Pfizer Reports China Trial Results for Lyrica

Pfizer reported mixed results from two China trials of Lyrica ® , an anti-seizure drug that is also effective against some forms of neuropathic and chronic pain. Lyrica successfully reduced pain in a Phase IV follow-up study of patients with postherpetic neuralgia (PHN), the pain that follows shingles. But Lyrica did not meet its endpoints in a Phase III trial among patients with painful diabetic peripheral neuropathy (pDPN). More details.... Stock Symbol: (NYSE: PFE) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.